Blindness News and Research

RSS

Innovative tool for tracking movement of infectious diseases

It may seem like a game of tag, but it's an innovative tool for teaching the fundamentals of epidemiology, the science of how infectious diseases move through a population.

7 Apr 2012

Public not as willing to pay for effective mental illness treatments

An analysis of a nationally representative sample of 710 adult respondents reveals that the public is less willing to pay to avoid mental illnesses compared to paying for treatment of medical conditions.

6 Apr 2012

SelectHealth announces 2012 Select 25 award recipients

SelectHealth is pleased to announce the recipients of the 2012 Select 25 award. The nonprofit health insurance carrier will give $2,500 to each of the 25 winners to assist them in their efforts to improve health and wellness, or to serve populations with special needs.

6 Apr 2012

Key finding in regulation of intraocular pressure in glaucoma

A six-year collaboration between two faculty members of Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine has yielded new insight regarding the regulation of intraocular pressure (IOP) in glaucoma - an irreversible blinding disease that causes progressive visual impairment due to optic nerve damage and is the leading cause of blindness worldwide.

6 Apr 2012

Recycled glasses costs twice as much as ready-made glasses

You might feel good sending your old reading glasses to a developing country. But a recent international study, led by the International Centre for Eyecare Education (ICEE), a collaborating partner in the Vision CRC, in Sydney, suggests it is far better to give $10 for an eye examination and a new pair of glasses if you want to help someone in desperate need, and it is far better for building capacity in these communities.

5 Apr 2012

Stress-induced tolerance can prevent glaucoma

Working in mice, scientists at Washington University School of Medicine in St. Louis have devised a treatment that prevents the optic nerve injury that occurs in glaucoma, a neurodegenerative disease that is a leading cause of blindness.

4 Apr 2012

Positive outcome from AiCuris’ Letermovir phase 2b trial on HCMV infections

AiCuris announced today that data on the positive outcome of Letermovir (AIC246) tested in a phase 2b trial in transplant patients will be disclosed at several international meetings on behalf of the AIC246 study team.

3 Apr 2012

JDRF, iCo Therapeutics partner for iCo-007 Phase II trial in DME

iCo Therapeutics, a Vancouver-based drug reprofiling company and JDRF, the largest charitable funder of type 1 Diabetes (T1D) research have joined forces to investigate a potential new treatment for one of the most common complications of diabetes, diabetic macular edema.

29 Mar 2012

Bariatric surgery may eliminate need for diabetes medication

Diabetes has become an epidemic in the United States, with the number of cases tripling over the last three decades. Most of those cases are Type 2 diabetes, which is linked to obesity and can lead to serious medical issues that range from heart disease to renal failure, blindness, and more.

29 Mar 2012

IU biologist to genetically modify variants of chlamydia

An Indiana University biologist has been awarded over $2.3 million from the National Institutes of Health to genetically modify variants of the human pathogen chlamydia in hopes of finding a vaccine for the most commonly reported bacterial infectious disease in the United States.

27 Mar 2012

Study provides important clue in type 1 diabetes

In type 1 diabetes (T1D), pancreatic beta cells die from a misguided autoimmune attack, but how and why that happens is still unclear. Now, JDRF-funded scientists from the Indiana University School of Medicine have found that a specific type of cellular stress takes place in pancreatic beta cells before the onset of T1D, and that this stress response in the beta cell may in fact help ignite the autoimmune attack.

23 Mar 2012

CNN examines nodding disease among children in Northern Uganda

CNN examines nodding disease, a seizure disorder that has affected at least 3,000 children in Northern Uganda, as well as children in Liberia, Sudan, and Tanzania.

21 Mar 2012

Positive data from Aerpio's AKB-9778 Phase 1 trial on DME

Aerpio Therapeutics, a clinical‐stage biopharmaceutical company focused on advancing innovative therapies for the treatment of diabetic eye disease and inflammatory bowel disease, today announced positive data from its Phase 1 trial of AKB-9778 for the treatment of diabetic macular edema.

21 Mar 2012

Single dose of X-ray radiation can prevent glaucoma

Jackson Laboratory researchers have demonstrated that a single, targeted x-ray treatment of an individual eye in young, glaucoma-prone mice provided that eye with apparently life-long and typically complete protection from glaucoma.

20 Mar 2012

Ampio completes partial planned interim review in Optina trial for diabetic macular edema

Ampio Pharmaceuticals, Inc., a biopharmaceutical company conducting clinical trials on its three lead drugs (Zertane completed two phase III studies, Ampion-completed proof of concept studies and Optina), licensing distribution of these drugs and engaged in further drug development, today announced that it completed the planned interim review of the first 50% of patients enrolled in the Optina trial for diabetic macular edema.

19 Mar 2012

ThromboGenics, Alcon collaborate to commercialize ocriplasmin outside the US

ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces today that it has entered into an agreement with Alcon (a division of Novartis), the global leader in eyecare, for the commercialization of ocriplasmin in all markets outside the U.S.

16 Mar 2012

Bayer HealthCare receives FDA approval for Natazia to treat HMB

Bayer HealthCare Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Natazia (estradiol valerate and estradiol valerate/dienogest) tablets for the treatment of heavy menstrual bleeding (HMB) that is not caused by any diagnosed conditions of the uterus (womb), in women who choose an oral contraceptive (OC) for contraception.

15 Mar 2012

Scientists grow rudimentary retina structure from blood cells

For the first time, scientists at the University of Wisconsin-Madison have made early retina structures containing proliferating neuroretinal progenitor cells using induced pluripotent stem (iPS) cells derived from human blood.

14 Mar 2012

Positive results from Bausch + Lomb, NicOx BOL‑303259‑X phase 2b study on OAG

Bausch + Lomb, the global eye health company, and NicOx S.A. today announced positive top-line results from the phase 2b study conducted with BOL‑303259‑X, a novel nitric oxide-donating prostaglandin F2‑alpha analog, in patients with open-angle glaucoma or ocular hypertension.

13 Mar 2012

Connect during MS Awareness Week

Multiple sclerosis is a life altering disease that affects each person in a unique and different way. MS destroys connections, divides minds from bodies, pulls people from their lives and away from one another. Therefore, it's only fitting that connections would be its greatest enemy.

12 Mar 2012